Literature DB >> 19458494

Silencing of focal adhesion kinase by tumor direct injection of small interfering RNA decreases in vivo tumor growth.

Kae Tsutsumi1, Takeshi Yamaura, Motowo Nakajima, Toshiyuki Honda, Tatsuhiko Kasaoka.   

Abstract

Focal adhesion kinase (FAK) is shown to be frequently correlated with malignancy of the tumor and poor prognosis of the diseases.Because FAK resides immediately downstream of the interaction of cell surface adhesion molecules and extracellular matricies, it is considered to be critical to regulate several cellular processes including growth, differentiation, adhesion, motility and apoptosis. However, the studies on the role of FAK related to cell proliferation have been limited even in vitro. Here, in order to validate the role of FAK in in vivo tumor formation and proliferation, we employed direct intratumoral injection of short hairpin RNA (shRNA) targeting FAK with cationic liposome. Using shRNAs targeting FAK selected from the constructed shRNA library for FAK and by optimization of in vivo delivery conditions, we demonstrated different patterns of the association of FAK inhibition with in vivo tumor formation/proliferation inhibition in two models, PC3M heterotopic xenograft and 4T1 orthotopic syngraft models. These observations indicated that the roles of FAK in tumorigenesis are different among the tumor species. In addition, we showed that ERK is the critical MAP kinase in the signaling pathway down stream of FAK in in vivo proliferation of 4T1 tumor cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19458494     DOI: 10.4161/cbt.8.13.8884

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  1 in total

1.  Novel murine tumour models depend on strain and route of inoculation.

Authors:  Qiang Fu; Andrew Satterlee; Yongjun Wang; Yuhua Wang; Dun Wang; Jingling Tang; Zhonggui He; Feng Liu
Journal:  Int J Exp Pathol       Date:  2016-07-28       Impact factor: 1.925

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.